Back to search
FDAFDA · Food and drugs·Recall number D-1171-2023

Rasagiline Tablets 0.5mg, 30-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A., NDC 0378-1270-93

Published September 27, 2023 · Recall initiated: August 2, 2023

Summary

FDA records drug Class II recall D-1171-2023, published September 27, 2023 and initiated August 2, 2023. Recalling firm: Aurobindo Pharma USA Inc.; Status: Terminated; Reported quantity: 9,890 bottles; Lot: Lot #: 3112444, Exp 8/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications - results obtained were below spec average.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Aurobindo Pharma USA Inc.
Distributor
USA nationwide
Lot
Lot #: 3112444, Exp 8/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rasagiline Tablets 0.5mg, 30-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A., NDC 0378-1270-93 recalled?

Yes. FDA published recall D-1171-2023 on September 27, 2023. Reported hazard: Failed dissolution specifications - results obtained were below spec average.

What should I do if I have this product?

Voluntary: Firm initiated · Letter